BOTHELL, WA and VANCOUVER, March 28, 2013 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott
Cormack, President and Chief Executive Officer, will provide a
corporate presentation at the Future Leaders in the Biotech IndustryConference on Friday, April 5, 2013 at 9:30 a.m. ET at the Millennium
Broadway Hotel in New York City.
A live audio webcast can be accessed through the Investor Relations page
of the OncoGenex website at www.oncogenex.com. The webcast replay will be archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries
Ltd. (NYSE: TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and
in patients with advanced, unresectable non-small cell lung cancer.
OGX-427 is in Phase 2 clinical development and OGX-225 is currently in
pre-clinical development. More information is available at www.OncoGenex.com
SOURCE OncoGenex Pharmaceuticals, Inc.